AI in healthcare is accelerating fast—but adoption without governance is risk. In this conversation, oncology and health policy leaders break down how clinicians and health systems should evaluate emerging AI tools: what FDA clearance vs approval really means, why “not FDA-approved” doesn’t automatically mean unsafe, and how laboratory-developed tests (LDTs) are already embedded in everyday care. We also explore real-world evidence, model drift, and why implementation—not innovation—is the true bottleneck for safe scale. If you’re assessing AI in imaging, diagnostics, clinical decision support, or workflow automation, this is your framework for asking smarter questions and protecting patients.